American Journal of Respiratory and Critical Care Medicine · 2008 · 101 citations · 23 references
MedicineOncologyRadiologyCancer ScreeningDiagnostic ToxicologyOncologic Nuclear MedicineLung CancerMalignant NeoplasmsPulmonary ToxicityTumor MarkersAsbestos Exposure MonitoringAsbestos Risk AssessmentAsbestos-related DiseaseAsbestosisLung Cancer RiskMesothelioma ScreeningPleural PlaquesSubjects
RATIONALE: Soluble mesothelin-related protein (SMRP) is raised in epithelial-type malignant mesothelioma (MM), but the utility of SMRP in screening for MM is unknown. OBJECTIVES: We aimed to evaluate SMRP in an asbestos-exposed cohort. METHODS: A total of 538 subjects were studied. Those with elevated SMRP (> or =2.5 nM) underwent further investigation including positron emission tomography/computed tomography. MEASUREMENTS AND MAIN RESULTS: Mean (+/-SD) SMRP in healthy subjects exposed to asbestos (n = 223) was 0.79 (+/-0.45) nM. Fifteen subjects had elevated SMRP, of whom one had lung cancer, which was successfully resected. Another with lung cancer was undetected by SMRP. No subjects were diagnosed with MM. Mean SMRP in healthy subjects was significantly lower than in subjects with pleural plaques alone (P < 0.01). CONCLUSIONS: This is the first large-scale prospective study of SMRP for screening for malignancy in asbestos-exposed individuals. A high false-positive rate was observed. SMRP seems unlikely to prove useful in screening for MM.
23
Mesothelin-family proteins and diagnosis of mesothelioma
Bruce Robinson, Jenette Creaney, Richard Lake et al. · The Lancet · 2003 · 532 citations